# Recursion Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/recursion-pharmaceuticals

- Industry: Software
- Headquarters: Salt Lake City, US
- Website: www.recursion.com
- Total disclosed funding: $427M
- Latest round: Series C (Sep 1, 2020)
- Investors on record: 22

## About

Founded in 2013 and based in Utah, US, Recursion Pharmaceuticals, Inc. operates as a biotechnology company. The company was co-founded by CEO Chris Gibson, Blake Borgeson, and Dean Li. Recursion Pharmaceuticals, Inc. trades on the NASDAQ GS under the ticker symbol RXRX, and in May 2023, the company acquired Cyclica, and Valence. In July 2023, the firm raised USD 50 million in PIPE funding from NVIDIA Corporation.

Recursion Pharmaceuticals utilizes an AI-based using machine learning robotics platform in testing various compounds on cellular disease models which helps in discovering new treatments. Recursion Pharmaceuticals combines an advanced infrastructure layer to generate proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology and navigate to new biological insights.

The company plans to use the July 2023 funding to speed up the development of its platform.

## Funding rounds

- Series C, Sep 1, 2020, $236M — Advantage Capital, EPIC Ventures, Two Sigma Investments, Lux Capital, Felicis Ventures, Casdin Capital, Laurion Capital Management, DCVC, Obvious, Mubadala Capital, Samsara BioCapital, Intermountain Ventures, Baillie Gifford, Leaps by Bayer, Catalio Capital Management
- Series C, Jul 15, 2019, $121M — CRV, Menlo Ventures, EPIC Ventures, Two Sigma Investments, Lux Capital, Baillie Gifford, Felicis Ventures, DCVC, AME Cloud Ventures, Obvious, Mubadala Capital, Intermountain Ventures, Texas Tech University System, Regents of the University of Minnesota
- Series B, Oct 3, 2017, $56M — Advantage Capital, CRV, Menlo Ventures, EPIC Ventures, Two Sigma Investments, Lux Capital, Mubadala Investment Company, Felicis Ventures, DCVC, AME Cloud Ventures, Obvious
- Series A, Dec 2, 2016, $2.1M — EPIC Ventures, Lux Capital, Felicis Ventures, DCVC, AME Cloud Ventures, Obvious
- Series A, Sep 14, 2016, $13M — EPIC Ventures, Lux Capital, Wild Basin Investments, DCVC, AME Cloud Ventures, Obvious

## Investors

- EPIC Ventures (https://capitalatlas.ai/funds/epic-ventures) — Series A, Series B, Series C
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B, Series C
- Wild Basin Investments (https://capitalatlas.ai/funds/wild-basin-investments) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A, Series B, Series C
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A, Series B, Series C
- Obvious (https://capitalatlas.ai/funds/obvious) — Series A, Series B, Series C
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Series A, Series B, Series C
- Advantage Capital — Series B, Series C
- CRV (https://capitalatlas.ai/funds/crv) — Series B, Series C
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series B, Series C
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series B, Series C
- Mubadala Investment Company — Series B
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series C
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series C
- Intermountain Ventures (https://capitalatlas.ai/funds/intermountain-ventures) — Series C
- Texas Tech University System — Series C
- Regents of the University of Minnesota — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- Laurion Capital Management — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C